Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANGUINATE in Sickle Cell Disease Vaso-Occlusive Crisis
NCT02672540Phase 2Completed
- Sponsor
- Prolong Pharmaceuticals
- Start
- Jul 2016
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, single-blind trial of Sanguinate in sickle cell disease (SCD) (2 arms), sponsored by Prolong Pharmaceuticals. Primary endpoint: Time to readiness for discharge from in hospital stay up to 7 Days. Started Jul 2016; status: completed.
02
Drugs
Sanguinate
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02672540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672540.